Overview

Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne

Status:
Completed
Trial end date:
2001-09-01
Target enrollment:
Participant gender:
Summary
This study investigates the safety and efficacy of MBI 226 2.5% and 5.0% Acne Solutions, applied topically for six weeks, in the treatment of acne.
Phase:
Phase 2
Details
Lead Sponsor:
BioWest Therapeutics Inc
Treatments:
Antimicrobial Cationic Peptides
Omiganan pentahydrochloride
Pharmaceutical Solutions